Kate Dingwall is a clinical development leader committed to designing and optimizing programs that bring meaningful advancements to patients and caregivers. As Senior Vice President of Development Operations at Zura Bio, she guides the development and execution of clinical programs for autoimmune diseases, ensuring that trials are patient-centered, well-organized, and accessible. With a background in oncology and immuno-oncology drug development, Kate previously served as Vice President of Clinical Development Operations and Clinical Science and Operations at Adaptimmune, where she helped shape programs to advance new cancer therapies. Before that, she held leadership roles at AstraZeneca, including Senior Director of Immuno-Oncology Program Management, working with cross-functional teams to support clinical trial operations. Kate is passionate about fostering collaboration and efficiency in clinical development, always keeping the needs of patients and caregivers at the heart of her work. She strives to ensure that trials run smoothly, support innovative treatments, and ultimately improve the experience and outcomes for those navigating complex health conditions.